All In Biotech

Drug Trial Radar · NCT04786795

MITE in the Treatment of Dyspepsia After Cholecystectomy

MITE (Compound Azintamide Enteric-coated Tablets) in the Treatment of Dyspepsia After Cholecystectomy: a Multicenter, Randomized, Superior, Parallel Controlled Clinical Study

Last checked: Nov 19, 2026Latest source record: Mar 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 990 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

990

Planned (sponsor's estimate)

Start

Mar 1, 2021

Primary completion

Feb 1, 2022

Study completion Feb 2022

Sponsor

Sponsor type
Academic, hospital or other
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To confirm the clinical efficacy of Compound Azintamide Enteric-coated Tablets in the treatment of patients with dyspepsia after cholecystectomy (such as abdominal distension, abdominal pain/abdominal discomfort, diarrhea/fatty stool, early satiety, belching, loss of appetite, etc.) by comparing with positive control drug, to observe its safety, and to evaluate the quality of life of subjects before and after treatment

Conditions

  • Patients With Dyspeptic Symptoms After Cholecystectomy

Interventions

  • Compound Azintamide Enteric-coated TabletsDrug

    the experimental group takes Compound Azintamide Enteric-coated Tablets.They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit

  • Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid TabletsDrug

    the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Symptom assessmentTime frame: 28days
  2. Efficacy evaluationTime frame: 28days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.